Bioavailability of Bumetanide in Grossly Oedematous Patients
- 1 June 1987
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 12 (6) , 440-443
- https://doi.org/10.2165/00003088-198712060-00004
Abstract
A pharmacokinetic study was undertaken to determine the bioavailability of bumetanide in grossly oedematous patients. Six nephrotic patients were administered bumetanide 2mg orally (as tablets) and intravenously as single doses, in a randomised fashion. Serum bumetanide concentration-time profiles were characterised. Data were fitted to a 2-compartment model (5 patients) and a 3-compartment model (1 patient). Analysis of the areas under the curves showed a bioavailability of 0.84 ± 0.2, which is similar to that in normal individuals. It is suggested that the bioavailability of oral bumetanide in oedematous patients is not altered significantly and that the apparent resistance to diuretics in such patients may be due to another cause.This publication has 6 references indexed in Scilit:
- The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.British Journal of Clinical Pharmacology, 1983
- The pharmacokinetics and pharmacodynamics of bumetanide in normal subjectsJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Determination of the diuretic bumetanide in biological fluids by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- Diuretic resistance: reduced bioavailability and effect of oral frusemide.BMJ, 1980
- Renal tubular secretion and effects of furosemideClinical Pharmacology & Therapeutics, 1980
- Effects of probenecid on furosemide kinetics and natriuresis in manClinical Pharmacology & Therapeutics, 1977